Lilly Dicerna Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Buzz is building for SELECT, the semaglutide CV outcomes trial, and ORBITA-2, a sham-controlled trial of PCI in stable CAD.

United statesLaura mckeownLos angelesAmit kheraLilly dicerna pharmaJoanna chikweTodd nealeMichael oriordanBayer janssenHealth innovation pavilionBristol myers squibbNational heartPopulation healthNovo nordiskBlood institute tiffany powell wileySinai medical center